Location of Repository

A long-term "memory" of HIF induction in response to chronic mild decreased oxygen after oxygen normalization

By Chandrashekhar D. Kamat, Jessica E Thorpe, Satyendra S Shenoy, Antonio Ceriello, Dixy E. Green, Linda A. Warnke and Michael A. Ihnat

Abstract

Background\ud Endothelial dysfunction (ED) is functionally characterized by decreased vasorelaxation, increased thrombosis, increased inflammation, and altered angiogenic potential, has been intimately associated with the progression and severity of cardiovascular disease. Patients with compromised cardiac function oftentimes have a state of chronic mild decreased oxygen at the level of the vasculature and organs, which has been shown to exacerbate ED. Hypoxia inducible factor (HIF) is a transcription factor complex shown to be the master regulator of the cellular response to decreased oxygen levels and many HIF target genes have been shown to be associated with ED.\ud \ud Methods\ud Human endothelial and aortic smooth muscle cells were exposed either to A) normoxia (21% O2) for three weeks, or to B) mild decreased oxygen (15% O2) for three weeks to mimic blood oxygen levels in patients with heart failure, or to C) mild decreased oxygen for two weeks followed by one week of normoxia ("memory" treatment). Levels of HIF signaling genes (HIF-1α, HIF-2α, VEGF, BNIP3, GLUT-1, PAI-1 and iNOS) were measured both at the protein and mRNA levels.\ud \ud Results\ud It was found that chronic exposure to mild decreased oxygen resulted in significantly increased HIF signaling. There was also a "memory" of HIF-1α and HIF target gene induction when oxygen levels were normalized for one week, and this "memory" could be interrupted by adding a small molecule HIF inhibitor to the last week of normalized oxygen. Finally, levels of ubiquitylated HIF-1α were reduced in response to chronic mild decreased oxygen and were not full restored after oxygen normalization.\ud \ud Conclusion\ud These data suggest that HIF signaling may be contributing to the pathogenesis of endothelial dysfunction and that normalization of oxygen levels may not be enough to reduce vascular stress.\ud \u

Topics: R1
Publisher: BioMed Central Ltd.
Year: 2007
OAI identifier: oai:wrap.warwick.ac.uk:561

Suggested articles

Preview

Citations

  1. (2007). 05; triple asterisk, P < 0.001 as compared to cells incubated in normoxia for three weeks.BMC Cardiovascular Disorders
  2. (2001). AL: HIF1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res
  3. (2003). AL: Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res
  4. (1995). AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. doi
  5. (2003). Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med doi
  6. (1990). BF: Relationship of endoneurial capillary abnormalities to type and severity of diabetic polyneuropathy. Diabetes doi
  7. (2003). Cancer Inst
  8. (2000). Carcinogenic nickel induces genes involved with hypoxic stress. Cancer Res
  9. (2005). Chakrabarti S: Vascular endothelial dysfunction in diabetic cardiomyopathy: Pathogenesis and potential treatment targets. Pharmacol Ther doi
  10. (2004). CY: Enhancement of hypoxiainduced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxiainducible factor-1alpha. Cancer Res
  11. (2001). Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. doi
  12. (2005). Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res
  13. (2001). E: Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1alpha protein by the oxidative stressor arsenite.
  14. (2002). Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. Jama doi
  15. (2004). Endothelial dysfunction and reactive oxygen species production in ischemia/reperfusion and nitrate tolerance. Gen Physiol Biophys
  16. (2004). Endothelial function: a critical determinant in atherosclerosis? Circulation doi
  17. (2000). Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. doi
  18. (2001). FS: HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. doi
  19. Gas exchange and hemodynamics during sleep.
  20. (1993). GL: Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNAbinding activity: implications for models of hypoxia signal transduction. Blood
  21. (1995). GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. doi
  22. (2004). Gleadle JM: Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxiainducible factor. doi
  23. (2004). Goldman MH: Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. doi
  24. (2005). Gorlach A: Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. Semin Cell Dev Biol doi
  25. GW: Selection of patients with chronic obstructive pulmonary disease for long-term oxygen therapy.
  26. (2002). Hypoxia and acidosis activate cardiac myocyte death through the doi
  27. (1995). Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res doi
  28. (2005). Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. doi
  29. (2005). Hypoxic induction of a HIF-1{alpha}- dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood doi
  30. (2001). Imura N: Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha. Biochem Biophys Res Commun doi
  31. (1999). Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood doi
  32. (1998). Interleukin 1beta decreases prostacyclin synthase activity in rat mesangial cells via endogenous peroxynitrite formation.
  33. (2006). JW: A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. doi
  34. JW: YC-1: a potential anticancer drug targeting hypoxia-inducible factor doi
  35. (1987). Kappagoda T: Endothelium-dependent relaxation in aorta of BB rat. Diabetes doi
  36. (2005). Lip GY: Endothelial function and its assessment. Expert Opin Investig Drugs doi
  37. (2006). Liu Y: Inhibition of hypoxia-inducible factor-1alpha and endothelial progenitor cell differentiation by adenoviral transfer of small interfering RNA in vitro. doi
  38. (2005). MA: A novel multidrug resistance phenotype of bladder tumor cells grown on Matrigel or SIS gel. Cancer Lett doi
  39. (1997). Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med doi
  40. (2004). Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet doi
  41. (1997). Nawroth PP: Advanced glycation end productinduced activation of NF-kappaB is suppressed by alphalipoic acid in cultured endothelial cells. Diabetes doi
  42. (1997). Nitric oxide and ocular blood flow in patients with IDDM. Diabetes doi
  43. (2004). Nitric oxide, oxidants, and protein tyrosine nitration. doi
  44. (2005). NO restores HIF1alpha hydroxylation during hypoxia: role of reactive oxygen species. Free Radic Biol Med doi
  45. (1990). Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. doi
  46. (2006). Oxidative stress, endothelial function and angiogenesis induced by cell therapy and gene therapy. Curr Pharm Biotechnol doi
  47. (1999). p42/p44 mitogen-activated protein kinases phosphorylate hypoxiainducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. doi
  48. (2005). PAI-1 and atherothrombosis. doi
  49. (1999). PE: Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic Biol Med doi
  50. (1999). PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature
  51. (2001). PK: Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ
  52. (2004). Poellinger L: Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function. Diabetes doi
  53. (2000). PT: Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. doi
  54. (2005). Ratcliffe PJ: Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol doi
  55. (1997). Ratcliffe PJ: Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood
  56. (2003). Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science doi
  57. (2005). Relation of endothelial cell function to erectile dysfunction: implications for treatment. doi
  58. (1998). RK: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. doi
  59. (2006). Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res doi
  60. (2005). S: Longterm effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation
  61. (2000). SC: Antioxidant/pro-oxidant equilibrium regulates HIF-1alpha and NF-kappa B redox sensitivity. Evidence for inhibition by glutathione oxidation in alveolar epithelial cells. doi
  62. (1993). Semenza GL: Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia.
  63. (2003). Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: doi
  64. (2006). Tarpey MM: Moderate hypoxia induces xanthine oxidoreductase activity in arterial endothelial cells. Free Radic Biol Med doi
  65. (2005). The role of nitric oxide in cardiovascular diseases. Mol Aspects Med doi
  66. (1992). TJ: HMEC-1: establishment of an immortalized human microvascular endothelial cell line. doi
  67. (2004). TM: Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem doi
  68. (2005). Udelson JE: Metabolic imaging with beta-methyl-p-[(123)I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation doi
  69. (1997). Varesio L: Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine. doi
  70. (1999). W: Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood doi
  71. Woolcock AJ: Arterial blood gas tension changes at the start of exercise in chronic obstructive pulmonary disease.
  72. (1989). Zaloga GP: Bedside analysis of arterial blood gases and electrolytes during and after cardiac surgery. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.